Skip to main content

Table 1 Patient and procedural characteristics

From: Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds

  All patients (n = 657) Patients with diabetes (n = 138) Patients without diabetes (n = 519) P-value
Age (years) 63 ± 12 65 ± 11 62 ± 12 0.015
Male 519/657 (79.0%) 107/138 (77.5%) 412/519 (79.4%) 0.722
Hypertension 478/657 (72.8%) 117/138 (84.8%) 361/519 (69.6%) < 0.001
Smoking 273/657 (41.6%) 48/138 (34.8%) 225/519 (43.3%) 0.086
Family History 138/657 (21.0%) 21/138 (15.2%) 117/519 (22.5%) 0.078
Hyperlipidemia 268/657 (40.8%) 76/138 (55.1%) 192/519 (37.0%) < 0.001
Prior CABG 14/657 (2.1%) 5/138 (3.6%) 9/519 (1.7%) 0.186
Prior PCI 181/657 (27.5%) 48/138 (34.8%) 133/519 (25.6%) 0.042
Prior stroke/TIA 27/657 (4.1%) 11/138 (8.0%) 16/519 (3.1%) 0.020
eGFR (ml/min) 83 ± 23 76 ± 25 84 ± 22 < 0.001
LVEF (%) 52 ± 8 53 ± 7 52 ± 9 0.590
Silent/stable angina 219/657 (33.3%) 56/138 (40.6%) 163/519 (31.4%) 0.054
Unstable Angina 78/657 (11.9%) 20/138 (14.5%) 58/519 (11.1%) 0.356
NSTEMI 191/657 (29.1%) 33/138 (23.9%) 158/519 (30.4%) 0.163
STEMI 166/657 (25.3%) 28/138 (20.3%) 138/519 (26.6%) 0.161
Lesion characteristics
 LAD treated with BRS 301/657 (45.8%) 68/138 (49.3%) 233/519 (44.9%) 0.411
 LCX treated with BRS 161/657 (24.4%) 36/138(26.1%) 125/519(24.1%) 0.708
 RCA treated with BRS 194/657 (29.7%) 34/138 (24.6%) 160/519 (30.8%) 0.190
 Graft treated with BRS 1/657 (0.2%) 0/138 (0%) 1/519 (0.2%) 1
 Ostial lesion 53/657 (8.1%) 10/138 (7.2%) 43/519 (8.3%) 0.824
 CTO 11/657(1.7%) 2/138 (1.4%) 15/519 (2.9%) 0.546
Bifurcation 82/657(12.5%) 13/138(9.4%) 69/519(13.3%) 0.281
 At least one lesion type B2 or C 297/657 (45.2%) 62/138 (44.9%) 235/519 (45.3%) 0.982
Procedural characteristics
 Number of vessels treated with BVS 1.2 ± 0.4 1.2 ± 0.5 1.1 ± 0.4 0.095
 Number of BRS per patient 1.4 ± 0.8 1.5 ± 0.9 1.4 ± 0.8 0.181
vHybrid BRS + DES 330/657(50.2%) 56/138(40.6%) 274/519(52.8%) 0.014
 Predilatation 653/657(99.4%) 136/138(98.6%) 517/519(99.6%) 0.196
 Diameter predilatation ballon (mm) 2.80 ± 0.37 2.83 ± 0.36 2.80 ± 0.37 0.367
Minimum stent diameter per patient (mm) 2.97 ± 0.38 2.96 ± 0.36 2.98 ± 0.38 0.572
 Total implanted length per patient (mm) 27.5 ± 18.9 29.0 ± 19.4 27.2 ± 18.8 0.324
 Postdilatation 306/657(46.6%) 71/138(51.4%) 235/519(45.3%) 0.232
 Preprocedural RVD, mm 2.93 ± 0.67 2.91 ± 0.77 2.94 ± 0.65 0.728
 Preprocedural MLD, mm 0.61 ± 0.51 0.71 ± 0.41 0.58 ± 0.54 0.026
 % stenosis per lesion 78.2 ± 17.9 74.6 ± 13.6 79.4 ± 18.8 0.014
Angiographic Outcome
 Postprocedural RVD, mm 3.0 ± 0.5 3.0 ± 0.4 3.0 ± 0.5 0.760
vPostprocedural MLD, mm 2.5 ± 0.5 2.5 ± 0.5 2.5 ± 0.5 0.135
 Residual stenosis per lesion (%) 14.5 ± 10.8 16.7 ± 13.2 13.7 ± 9.9 0.018
 MLD/nominal BRS diameter 0.84 ± 0.13 0.82 ± 0.16 0.85 ± 0.13 0.101
 Lumen Gain, mm 1.63 ± 0.62 1.61 ± 0.61 1.68 ± 0.56 0.382
 Optimal implantation technique 311/657 (47.3%) 74/138 (53.6%) 237/519 (45.7%) 0.117
 Overlap 74/657 (11.3%) 12/138 (8.7%) 62/519 (11.9%) 0.357
 Clopidogrel 200/657 (30.4%) 51/138 (37.0%) 149/519 (28.7%) 0.077
 Prasugrel 324/657 (49.3%) 67/138 (48.6%) 257/519 (49.5%) 0.915
 Ticagrelor 132/657 (20.1%) 19/138 (13.8%) 113/519 (21.8%) 0.076
  1. P < 0.05 as statistically significant are in bold